Tau-targeting therapies for Alzheimer disease
Тип публикации: Journal Article
Дата публикации: 2018-06-12
SCImago Q1
Tоп 10% SCImago
WOS Q1
БС1
SJR: 7.083
CiteScore: 33.1
Impact factor: 31.2
ISSN: 17594758, 17594766
PubMed ID:
29895964
Cellular and Molecular Neuroscience
Neurology (clinical)
Краткое описание
Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, resulting in cognitive deficits and eventually dementia. Amyloid-β (Aβ) peptide and tau protein are the primary components of the plaques and tangles, respectively. In the decades since Aβ and tau were identified, development of therapies for AD has primarily focused on Aβ, but tau has received more attention in recent years, in part because of the failure of various Aβ-targeting treatments in clinical trials. In this article, we review the current status of tau-targeting therapies for AD. Initially, potential anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy. Currently, the majority of tau-targeting therapies in clinical trials are immunotherapies, which have shown promise in numerous preclinical studies. Given that tau pathology correlates better with cognitive impairments than do Aβ lesions, targeting of tau is expected to be more effective than Aβ clearance once the clinical symptoms are evident. With future improvements in diagnostics, these two hallmarks of the disease might be targeted prophylactically. Interest in tau-targeting strategies for Alzheimer disease is increasing, in part because of the failure of various amyloid-β-targeting treatments in clinical trials. Congdon and Sigurdsson review the current status of tau-targeting therapies, including anti-tau drugs and immunotherapies.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.
Топ-30
Журналы
|
5
10
15
20
25
30
35
40
45
|
|
|
bioRxiv
45 публикаций, 4.52%
|
|
|
International Journal of Molecular Sciences
40 публикаций, 4.02%
|
|
|
Journal of Alzheimer's Disease
36 публикаций, 3.61%
|
|
|
Cells
16 публикаций, 1.61%
|
|
|
Frontiers in Aging Neuroscience
16 публикаций, 1.61%
|
|
|
ACS Chemical Neuroscience
16 публикаций, 1.61%
|
|
|
Ageing Research Reviews
12 публикаций, 1.2%
|
|
|
Scientific Reports
11 публикаций, 1.1%
|
|
|
Molecular Neurodegeneration
11 публикаций, 1.1%
|
|
|
Biomedicines
10 публикаций, 1%
|
|
|
Frontiers in Neuroscience
10 публикаций, 1%
|
|
|
European Journal of Medicinal Chemistry
10 публикаций, 1%
|
|
|
Alzheimer's and Dementia
9 публикаций, 0.9%
|
|
|
Molecules
9 публикаций, 0.9%
|
|
|
Frontiers in Molecular Neuroscience
9 публикаций, 0.9%
|
|
|
Acta neuropathologica communications
9 публикаций, 0.9%
|
|
|
Biomedicine and Pharmacotherapy
9 публикаций, 0.9%
|
|
|
medRxiv
9 публикаций, 0.9%
|
|
|
Pharmaceuticals
8 публикаций, 0.8%
|
|
|
Frontiers in Neurology
8 публикаций, 0.8%
|
|
|
Nature Communications
8 публикаций, 0.8%
|
|
|
Molecular Neurobiology
8 публикаций, 0.8%
|
|
|
Advances in Protein Chemistry and Structural Biology
8 публикаций, 0.8%
|
|
|
Frontiers in Pharmacology
7 публикаций, 0.7%
|
|
|
Bioorganic Chemistry
6 публикаций, 0.6%
|
|
|
Neural Regeneration Research
6 публикаций, 0.6%
|
|
|
Current Alzheimer Research
5 публикаций, 0.5%
|
|
|
Biomolecules
5 публикаций, 0.5%
|
|
|
Brain Sciences
5 публикаций, 0.5%
|
|
|
5
10
15
20
25
30
35
40
45
|
Издатели
|
50
100
150
200
250
|
|
|
Elsevier
239 публикаций, 24%
|
|
|
Springer Nature
166 публикаций, 16.67%
|
|
|
MDPI
124 публикации, 12.45%
|
|
|
Wiley
70 публикаций, 7.03%
|
|
|
Frontiers Media S.A.
67 публикаций, 6.73%
|
|
|
openRxiv
54 публикации, 5.42%
|
|
|
American Chemical Society (ACS)
48 публикаций, 4.82%
|
|
|
Bentham Science Publishers Ltd.
31 публикация, 3.11%
|
|
|
Taylor & Francis
26 публикаций, 2.61%
|
|
|
SAGE
24 публикации, 2.41%
|
|
|
IOS Press
23 публикации, 2.31%
|
|
|
Royal Society of Chemistry (RSC)
18 публикаций, 1.81%
|
|
|
Oxford University Press
12 публикаций, 1.2%
|
|
|
American Association for the Advancement of Science (AAAS)
9 публикаций, 0.9%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
7 публикаций, 0.7%
|
|
|
Public Library of Science (PLoS)
6 публикаций, 0.6%
|
|
|
Hindawi Limited
6 публикаций, 0.6%
|
|
|
Portland Press
3 публикации, 0.3%
|
|
|
American Society for Biochemistry and Molecular Biology
3 публикации, 0.3%
|
|
|
Impact Journals
2 публикации, 0.2%
|
|
|
S. Karger AG
2 публикации, 0.2%
|
|
|
European Molecular Biology Organization
2 публикации, 0.2%
|
|
|
Medknow
2 публикации, 0.2%
|
|
|
IMR Press
2 публикации, 0.2%
|
|
|
Apex Publishing
2 публикации, 0.2%
|
|
|
Spandidos Publications
1 публикация, 0.1%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
1 публикация, 0.1%
|
|
|
Mary Ann Liebert
1 публикация, 0.1%
|
|
|
Massachusetts Medical Society
1 публикация, 0.1%
|
|
|
50
100
150
200
250
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Войти с ORCID
Метрики
996
Всего цитирований:
996
Цитирований c 2025:
196
(19.68%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Congdon E. E., Sigurdsson E. M. Tau-targeting therapies for Alzheimer disease // Nature Reviews Neurology. 2018. Vol. 14. No. 7. pp. 399-415.
ГОСТ со всеми авторами (до 50)
Скопировать
Congdon E. E., Sigurdsson E. M. Tau-targeting therapies for Alzheimer disease // Nature Reviews Neurology. 2018. Vol. 14. No. 7. pp. 399-415.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1038/s41582-018-0013-z
UR - https://doi.org/10.1038/s41582-018-0013-z
TI - Tau-targeting therapies for Alzheimer disease
T2 - Nature Reviews Neurology
AU - Congdon, Erin E.
AU - Sigurdsson, Einar M
PY - 2018
DA - 2018/06/12
PB - Springer Nature
SP - 399-415
IS - 7
VL - 14
PMID - 29895964
SN - 1759-4758
SN - 1759-4766
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2018_Congdon,
author = {Erin E. Congdon and Einar M Sigurdsson},
title = {Tau-targeting therapies for Alzheimer disease},
journal = {Nature Reviews Neurology},
year = {2018},
volume = {14},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1038/s41582-018-0013-z},
number = {7},
pages = {399--415},
doi = {10.1038/s41582-018-0013-z}
}
Цитировать
MLA
Скопировать
Congdon, Erin E., et al. “Tau-targeting therapies for Alzheimer disease.” Nature Reviews Neurology, vol. 14, no. 7, Jun. 2018, pp. 399-415. https://doi.org/10.1038/s41582-018-0013-z.
Ошибка в публикации?